- Stocks
- Pharma & Healthcare
- Transgene Biote
Transgene Biote share price
NSE: TRABIPharma & HealthcareBiotechnology
Transgene Biote at a glance
With a market capitalisation of ₹23 Cr, it ranks 3525th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Biotechnology.
Its return on equity was −19.7% in FY26. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹0 Cr (−37.5% year on year) and net profit −₹0 Cr, on a consolidated basis. Promoters held 23.64% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹23 CrRank 3525 on NSE
- Price to book
- 1.79×FY26
- EPS (TTM)
- −₹0.22to Q4 FY26
- ROE
- −19.7%FY26
- ROCE
- −0.5%FY26
- Debt to equity
- 2.05FY26
- Net profit margin
- −782.6%FY26
- Book value / share
- ₹1.11FY26
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | — | — | — | — | — |
Transgene Biote quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Revenue YoY | −50.0% | +20.0% | +60.0% | +60.0% | 0.0% | −16.7% | −37.5% | −37.5% |
| Net profit | ₹0 Cr | −₹0 Cr | −₹0 Cr | −₹1 Cr | −₹0 Cr | −₹0 Cr | −₹0 Cr | −₹0 Cr |
| Net profit YoY | — | — | — | — | −315.0% | — | — | — |
| Net margin | 400.0% | −116.7% | −112.5% | −887.5% | −860.0% | −780.0% | −740.0% | −920.0% |
| EPS | ₹0.03 | −₹0.01 | −₹0.01 | −₹0.09 | −₹0.06 | −₹0.05 | −₹0.05 | −₹0.06 |
Transgene Biote financials
| Item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | — |
| Operating profit | −₹10 Cr | −₹10 Cr | −₹6 Cr | −₹1 Cr | −₹1 Cr | — |
| Net profit | −₹10 Cr | −₹10 Cr | −₹6 Cr | −₹1 Cr | −₹1 Cr | — |
| EPS (₹) | −₹1.00 | −₹1.00 | −₹1.00 | ₹0.00 | ₹0.00 | — |
| Cash from operations | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹1 Cr | — |
| Total debt | ₹5 Cr | ₹5 Cr | ₹5 Cr | ₹5 Cr | ₹6 Cr | ₹7 Cr |
| Shareholders' equity | ₹22 Cr | ₹17 Cr | ₹11 Cr | ₹11 Cr | ₹10 Cr | ₹8 Cr |
Transgene Biote shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 23.64% | 23.64% | 23.64% | 23.64% | 23.64% | 23.64% |
| Non-institutions | 76.36% | 76.36% | 76.36% | 76.36% | 76.36% | 76.36% |
Transgene Biote vs peers
The listed Pharma & Healthcare companies nearest to Transgene Biote by market capitalisation.
Ask anything about Transgene Biote
Pivot answers on the live chart with evidence you can check, and tests strategies against TRABI's own history. Try: “Why has TRABI moved over the last three months?” · “Backtest a 50-day moving-average crossover on TRABI over five years” · “Compare TRABI with PARMAX on margins and valuation”
Frequently asked questions about Transgene Biote
What is the market cap of Transgene Biote?
Transgene Biote's market capitalisation is ₹23 Cr (₹23 Cr) at the 22 Oct 2026 close, ranking 3525th among the NSE companies Pivot tracks.
What is the ROE and ROCE of Transgene Biote?
Return on equity was −19.7% in FY26 and return on capital employed was −0.5% in FY26 (consolidated figures).
Is Transgene Biote a debt-free company?
No. Transgene Biote's debt-to-equity ratio was 2.05 in FY26, with total debt of ₹7 Cr.
What were Transgene Biote's latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Transgene Biote reported revenue of ₹0 Cr, −37.5% year on year, and net profit of −₹0 Cr.
What is the shareholding pattern of Transgene Biote?
As of 30 Jun 2026: promoters 23.64%, non-institutions 76.36%.
Who are Transgene Biote's competitors?
The listed Pharma & Healthcare companies closest to Transgene Biote by market cap are Parmax Pharma, SUPHA PHARMACHE, Hamps Bio, Rekvina Labs, Adeshwar Medite and Maitri.
Is Transgene Biote a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Transgene Biote's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on TRABI against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with T · all NSE stocks · this page as text